Treatment of Recurrent Clostridium Difficile Infection With RBX7455: A Dose-ranging, Prospective, Single Center, Open Label Phase I Trial
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2018
At a glance
- Drugs RBX 7455 (Primary)
- Indications Clostridium infections
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 09 Jan 2018 According to a Rebiotix medis release, data will be presented in 2018.
- 10 May 2017 Planned number of patients changed from 20 to 40.
- 04 Jan 2017 According to a Rebiotix media release, first patient has been treated in this study.